Dear All, I was delighted to learn today that NIAID has released RFA-AI-24-069, a notice of funding opportunity (NOFO) soliciting applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). The CAPT-CEPs will focus on developing preclinical assays, tools, and models for robust phage therapy R&D and advancing phage clinical research. Applications are due
Dear All (and with thanks to Patricia Bradford for leading on this newsletter), Did you know you can access raw datasets of antimicrobial susceptibility surveillance data that have been generated by the pharmaceutical industry? Indeed such datasets exist and we’d like to ensure everyone is aware of their availability and potential! Background: The 20 Oct
Dear All (and with thanks to Damiano for co-authoring), We have exciting news from the G7 Health Ministers’ Meeting, which was held in person in Ancona on 9-11 October 2024, and the accompanying G7 Joint Finance and Health Ministers’ Meeting, which took place in a hybrid format on 10 October 2024. At the press conference closing
Dear All (and with thanks to Kevin for co-authoring and also a wonkish alert … get your coffee and settle in for the details), If you’ve been around the antibiotic ecosystem for a while, you’ve hopefully heard the story of the 2019 bankruptcy of Achaogen and the subsequent loss to the entire world of its
This is the fifth of a 5-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a second (28 Sep 2023) newsletter that expands on the EPA concept note, a third (12 Jan 2024) newsletter about ending the use of streptomycin spray on citrus crops, and a 4th newsletter (27 Jan 2024) containing some additional resources. Dear All, Excitingly, the US EPA
Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. 28 Oct 2024 addendum and another way to get a view of the day: Hosted by Cesar Arias, Editor-in-Chief of Antimicrobial Agents and Therapy, John and Prabha Fernandes recorded a podcast discussion of the HLM. Dear All (and with thanks to Damiano
Dear All, A new paper from Anthony McDonnell and a team led by the Center for Global Development extends estimates of the health-related impact of AMR (e.g., death) to a consideration of the economic ($) cost of AMR. To follow the plot, here are the links you will need: The new paper: “Forecasting the Fallout
Dear All, The AMR HLM (High-Level Meeting) at the UN General Assembly starts at 10a ET today. You can watch it here on UN TV: https://webtv.un.org/en/asset/k11/k11knc6w2t Addendum: It’s available for replay at that same link. See also the 1 Oct 2024 newsletter for a review of the HLM. All best wishes, –jr John H. Rex, MD
Dear All, The peri-UNGA week is generating a lot of activity! Having about a year ago launched a £30m fund for support of AMR innovation with a call for therapeutic projects (30 Oct 2023 newsletter; I am told that awards will be announced soon), PACE (Pathways to Antimicrobial Clinical Efficacy, a joint project of LifeArc,
Dear All, I have just learned that in parallel with the 26 Sep 2024 High-Level Meeting on AMR at the UN General Assembly, a day of virtual advocacy in support of PASTEUR is being organized by The Infectious Diseases Society of America, BIO, Cystic Fibrosis Foundation, Partnership to Fight Infectious Diseases, and The Pew Charitable